The Diagnostic Logic Behind a Low Sodium

A low serum sodium is a problem of water balance, not salt intake, and the guideline logic reflects that. The 2014 European clinical practice guideline on hyponatraemia, developed jointly by endocrinology, intensive care, and nephrology societies, moves through a fixed sequence: first confirm the blood is genuinely hypotonic, then read the urine to see whether the kidney is holding or excreting water, then judge whether the effective circulating volume is low, normal, or high. A cause is assigned only after those three questions are answered. And treatment is governed by a second principle that has nothing to do with the underlying cause: the rate at which sodium is raised can injure the brain as surely as the low value itself.

Tonicity is the first gate

Sodium is reported as a concentration, a ratio of solute to water, so a low number can mean too much water or a measurement artifact rather than a true deficit of tonicity. The guideline defines hyponatraemia as a serum sodium below 135 mmol/L and grades it biochemically as mild (130 to 135), moderate (125 to 129), and profound (below 125). Before any of that matters, the clinician confirms the state is truly hypotonic, meaning effective serum osmolality below 275 mOsm/kg.

Two traps live here. Isotonic hyponatraemia, the old pseudohyponatraemia of very high lipids or paraproteins, is a laboratory effect and not a water problem. Hypertonic hyponatraemia, driven by hyperglycaemia or mannitol, reflects water pulled into the vascular space by another osmole, so the low sodium partly corrects itself once glucose is managed. Treating either as though the body held excess free water would be a category error. Confirming tonicity keeps the reasoning honest.

Reading the urine

Once the state is truly hypotonic, the urine becomes the most informative test. Urine osmolality at or below roughly 100 mOsm/kg tells you the kidney is diluting appropriately, which points to a water-intake or low-solute problem such as primary polydipsia or a diet too thin in protein and salt to carry off the water consumed. A urine osmolality above 100 in the face of low serum tonicity means antidiuretic hormone is acting when physiology says it should be switched off, so free water is being retained inappropriately.

Urine sodium then separates the causes of that retention. A value at or below 30 mmol/L signals a low effective arterial blood volume, which occurs in true fluid loss and in the edematous states of heart failure and cirrhosis where the circulation is full yet the kidney senses underfilling. A urine sodium above 30 mmol/L, in a patient who looks euvolaemic and eats a normal diet, points toward the syndrome of inappropriate antidiuresis. Diuretics, kidney disease, and adrenal or thyroid deficiency all confound these readings, which is why no single number decides the diagnosis.

Volume completes the map

Clinical volume assessment sorts the hypotonic causes into hypovolaemic, euvolaemic, and hypervolaemic groups, and it is the step most vulnerable to bedside error. The syndrome of inappropriate antidiuresis sits in the euvolaemic column and remains a diagnosis of exclusion: it requires hypotonicity, concentrated urine, a urine sodium that is not suppressed, and the absence of adrenal insufficiency, hypothyroidism, diuretic use, and renal failure. The framework matters because the same sodium value carries opposite instructions. A hypovolaemic patient needs volume; a hypervolaemic patient in heart failure needs the opposite. Skipping the volume question is how the right number gets the wrong treatment.

The correction rate is where the danger lives

The classification tells you why the sodium is low. A separate rule governs how fast to raise it, and here the evidence is unusually specific about harm. In chronic hyponatraemia the brain adapts by extruding organic osmoles so its cells do not swell. Raise the serum sodium quickly and that same adaptation now pulls water out of neurons, producing osmotic demyelination, a delayed and often devastating injury classically seen in the pons. To guard against it, the guideline caps the rise at no more than 10 mmol/L in the first 24 hours and 8 mmol/L in each subsequent 24 hours, and it recommends actively re-lowering the sodium with dextrose in water or desmopressin if that ceiling is breached.

The exception is acute, severely symptomatic hyponatraemia with seizures, obtundation, or cardiorespiratory distress, where cerebral edema is the immediate threat. There the guideline calls for a prompt 150 mL bolus of 3% hypertonic saline aiming for a modest 5 mmol/L rise to relieve pressure, then a stop rather than a race to normal. The target is a controlled nudge, not a full correction.

What newer evidence sharpens

The guideline's limits were built largely from case analysis, and more recent work has refined how to read them. A 2023 NEJM Evidence cohort and later systematic reviews, including a 2024 meta-analysis in Kidney Medicine, found that osmotic demyelination clusters around identifiable host factors: alcohol use disorder, malnutrition, hypokalaemia, liver disease, and a very low presenting sodium. A 2023 systematic review documented that many demyelination cases followed rapid correction, yet a meaningful fraction occurred even when correction stayed under the guideline limit. The direction of the evidence is that the correction ceiling is a safeguard rather than a guarantee, and that the highest-risk patients warrant even slower, closely monitored targets. The classification framework and the rate limit work together: one names the problem, the other keeps the fix from becoming the injury.

This article is educational and is not a substitute for individual medical advice.